727 related articles for article (PubMed ID: 27048870)
1. Efficacy and Safety of Pulmonary Arterial Hypertension-specific Therapy in Pulmonary Arterial Hypertension: A Meta-analysis of Randomized Controlled Trials.
Liu HL; Chen XY; Li JR; Su SW; Ding T; Shi CX; Jiang YF; Zhu ZN
Chest; 2016 Aug; 150(2):353-66. PubMed ID: 27048870
[TBL] [Abstract][Full Text] [Related]
2. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.
Zheng YG; Ma H; Hu EC; Liu G; Chen G; Xiong CM
Pulm Pharmacol Ther; 2014 Dec; 29(2):241-9. PubMed ID: 25173912
[TBL] [Abstract][Full Text] [Related]
3. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J; Gao Y; Deng B; Liu K
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD004434. PubMed ID: 33765691
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
Barnes H; Brown Z; Burns A; Williams T
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension: A meta-analysis focusing on 6MWD.
He CJ; Chen SJ; Wang J; Zhu CY; Yin YH
Pulm Pharmacol Ther; 2015 Jun; 32():24-8. PubMed ID: 25843006
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy in pulmonary arterial hypertension: a meta-analysis.
Bai Y; Sun L; Hu S; Wei Y
Cardiology; 2011; 120(3):157-65. PubMed ID: 22212696
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary Arterial Hypertension-Specific Drug Therapy in COPD Patients with Severe Pulmonary Hypertension and Mild-to-Moderate Airflow Limitation.
Calcaianu G; Canuet M; Schuller A; Enache I; Chaouat A; Kessler R
Respiration; 2016; 91(1):9-17. PubMed ID: 26492415
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis.
Coeytaux RR; Schmit KM; Kraft BD; Kosinski AS; Mingo AM; Vann LM; Gilstrap DL; Hargett CW; Heidenfelder B; Dolor RJ; McCrory DC
Chest; 2014 May; 145(5):1055-1063. PubMed ID: 24371842
[TBL] [Abstract][Full Text] [Related]
9. What is the position of pulmonary arterial hypertension-specific drug therapy in patients with Eisenmenger syndrome: A systematic review and meta-analysis.
Li Q; Kuang HY; Wu YH; Lu TW; Yi QJ
Medicine (Baltimore); 2019 May; 98(20):e15632. PubMed ID: 31096477
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis.
Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA
Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518
[TBL] [Abstract][Full Text] [Related]
11. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis.
Ryerson CJ; Nayar S; Swiston JR; Sin DD
Respir Res; 2010 Jan; 11(1):12. PubMed ID: 20113497
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy improves exercise capacity and reduces risk of clinical worsening in patients with pulmonary arterial hypertension: a meta-analysis.
Zhu B; Wang L; Sun L; Cao R
J Cardiovasc Pharmacol; 2012 Oct; 60(4):342-6. PubMed ID: 22691882
[TBL] [Abstract][Full Text] [Related]
14. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
[TBL] [Abstract][Full Text] [Related]
15. Treatment of sarcoidosis-associated pulmonary hypertension: A single centre retrospective experience using targeted therapies.
Keir GJ; Walsh SL; Gatzoulis MA; Marino PS; Dimopoulos K; Alonso R; Raposeiras-Roubin S; Renzoni EA; Maher TM; Wells AU; Wort SJ
Sarcoidosis Vasc Diffuse Lung Dis; 2014 Jul; 31(2):82-90. PubMed ID: 25078636
[TBL] [Abstract][Full Text] [Related]
16. Effects of oral treatments on clinical outcomes in pulmonary arterial hypertension: A systematic review and meta-analysis.
Zhang HD; Zhang R; Jiang X; Sun K; Wu DC; Jing ZC
Am Heart J; 2015 Jul; 170(1):96-103, 103.e1-14. PubMed ID: 26093869
[TBL] [Abstract][Full Text] [Related]
17. Incremental burden of disease in patients diagnosed with pulmonary arterial hypertension receiving monotherapy and combination vasodilator therapy.
Small M; Piercy J; Pike J; Cerulli A
Adv Ther; 2014 Feb; 31(2):168-79. PubMed ID: 24449285
[TBL] [Abstract][Full Text] [Related]
18. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
Petrovič M; Locatelli I
Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
[No Abstract] [Full Text] [Related]
19. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ
Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost.
Han X; Zhang Y; Dong L; Fang L; Chai Y; Niu M; Yu Y; Liu L; Yang X; Qu S; Li S
Respir Care; 2017 Apr; 62(4):489-496. PubMed ID: 28119496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
